Cargando…
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
BACKGROUND: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. METHODS: Among pat...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877961/ https://www.ncbi.nlm.nih.gov/pubmed/24369725 http://dx.doi.org/10.1186/1471-2407-13-606 |
_version_ | 1782297724789456896 |
---|---|
author | Ji, Wonjun Choi, Chang-Min Rho, Jin Kyung Jang, Se Jin Park, Young Soo Chun, Sung-Min Kim, Woo Sung Lee, Jung-Shin Kim, Sang-We Lee, Dae Ho Lee, Jae Cheol |
author_facet | Ji, Wonjun Choi, Chang-Min Rho, Jin Kyung Jang, Se Jin Park, Young Soo Chun, Sung-Min Kim, Woo Sung Lee, Jung-Shin Kim, Sang-We Lee, Dae Ho Lee, Jae Cheol |
author_sort | Ji, Wonjun |
collection | PubMed |
description | BACKGROUND: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. METHODS: Among patients at a tertiary referral hospital in Korea who initially responded well to gefitinib and later acquired resistance to treatment, we selected those with enough tissues obtained before EGFR-TKI treatment and after the onset of resistance to examine mutations by mass spectrometric genotyping technology (Asan-Panel), MET amplification by fluorescence in situ hybridization (FISH), and analysis of AXL status, epithelial-to-mesenchymal transition (EMT) and neuroendocrine markers by immunohistochemistry. RESULTS: Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del). Secondary T790M mutation was detected in 11 subjects (42.3%) and four of these patients had other co-existing resistance mechanisms; increased AXL expression was observed in 5/26 patients (19.2%), MET gene amplification was noted in 3/26 (11.5%), and one patient acquired a mutation in the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) gene. None of the patients exhibited EMT; however, increased CD56 expression suggesting neuroendocrine differentiation was observed in two patients. Interestingly, conversion from L858R-mutant to wild-type EGFR occurred in one patient. Seven patients (26.9%) did not exhibit any known resistance mechanisms. Patients with a T790M mutation showed a more favorable prognosis. CONCLUSION: The mechanisms and frequency of acquired EGFR-TKI resistance in Koreans are comparable to those observed in Western populations; however, more data regarding the mechanisms that drive EGFR-TKI resistance are necessary. |
format | Online Article Text |
id | pubmed-3877961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38779612014-01-03 Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer Ji, Wonjun Choi, Chang-Min Rho, Jin Kyung Jang, Se Jin Park, Young Soo Chun, Sung-Min Kim, Woo Sung Lee, Jung-Shin Kim, Sang-We Lee, Dae Ho Lee, Jae Cheol BMC Cancer Research Article BACKGROUND: Despite an initial good response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), resistance to treatment eventually develops. Although several resistance mechanisms have been discovered, little data exist regarding Asian patient populations. METHODS: Among patients at a tertiary referral hospital in Korea who initially responded well to gefitinib and later acquired resistance to treatment, we selected those with enough tissues obtained before EGFR-TKI treatment and after the onset of resistance to examine mutations by mass spectrometric genotyping technology (Asan-Panel), MET amplification by fluorescence in situ hybridization (FISH), and analysis of AXL status, epithelial-to-mesenchymal transition (EMT) and neuroendocrine markers by immunohistochemistry. RESULTS: Twenty-six patients were enrolled, all of whom were diagnosed with adenocarcinoma with EGFR mutations (19del: 16, L858R: 10) except one (squamous cell carcinoma with 19del). Secondary T790M mutation was detected in 11 subjects (42.3%) and four of these patients had other co-existing resistance mechanisms; increased AXL expression was observed in 5/26 patients (19.2%), MET gene amplification was noted in 3/26 (11.5%), and one patient acquired a mutation in the phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) gene. None of the patients exhibited EMT; however, increased CD56 expression suggesting neuroendocrine differentiation was observed in two patients. Interestingly, conversion from L858R-mutant to wild-type EGFR occurred in one patient. Seven patients (26.9%) did not exhibit any known resistance mechanisms. Patients with a T790M mutation showed a more favorable prognosis. CONCLUSION: The mechanisms and frequency of acquired EGFR-TKI resistance in Koreans are comparable to those observed in Western populations; however, more data regarding the mechanisms that drive EGFR-TKI resistance are necessary. BioMed Central 2013-12-27 /pmc/articles/PMC3877961/ /pubmed/24369725 http://dx.doi.org/10.1186/1471-2407-13-606 Text en Copyright © 2013 Ji et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ji, Wonjun Choi, Chang-Min Rho, Jin Kyung Jang, Se Jin Park, Young Soo Chun, Sung-Min Kim, Woo Sung Lee, Jung-Shin Kim, Sang-We Lee, Dae Ho Lee, Jae Cheol Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer |
title | Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer |
title_full | Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer |
title_fullStr | Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer |
title_full_unstemmed | Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer |
title_short | Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer |
title_sort | mechanisms of acquired resistance to egfr-tyrosine kinase inhibitor in korean patients with lung cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877961/ https://www.ncbi.nlm.nih.gov/pubmed/24369725 http://dx.doi.org/10.1186/1471-2407-13-606 |
work_keys_str_mv | AT jiwonjun mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT choichangmin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT rhojinkyung mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT jangsejin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT parkyoungsoo mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT chunsungmin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT kimwoosung mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT leejungshin mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT kimsangwe mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT leedaeho mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer AT leejaecheol mechanismsofacquiredresistancetoegfrtyrosinekinaseinhibitorinkoreanpatientswithlungcancer |